HOME > FEATURE
FEATURE
- COLUMN
- Off-Year Drug Price Revisions
- COMMENTARY
- Cost Effectiveness Assessment (2025-)
- Drug Approval & Reimbursement in 2026
- FY2026 Drug Pricing Reform
- Drug Approval & Reimbursement in 2025
- PMD Act Amendment
- Drug Approval & Reimbursement in 2024
- TRENDS
- MHLW Panel on Generic Industry Structure
- MHLW Panel on Pharmaceutical Regulations
- Drug Approval & Reimbursement in 2023
- FY2024 Reimbursement Reform
- MHLW Expert Panel on Comprehensive Policies
- Chuikyo on Off-Year Drug Price Revision
- FY2022 Drug Maker Employment Survey
- Jiho Survey: FY2022 Drug Price Revision
- FY2022 Drug Pricing Reform
- FY2021 Drug Maker Employment Survey